Latest stories on DYN
Dyne Therapeutics (DYN) reports inducement grants totaling 382,400 shares for 16 new hires
MarketChameleon52 · neutralgeneral
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario
Seeking Alpha58 · neutralanalyst
Stifel reiterates Dyne Therapeutics stock rating on trial data
Investing.com Analyst Ratings56 · neutralanalyst
Wainwright cuts Dyne Therapeutics stock price target on DM1 assumptions
Investing.com Analyst Ratings34 · bearishanalyst
Cantor Fitzgerald reiterates Dyne Therapeutics stock rating
Investing.com Analyst Ratings50 · neutralanalyst
Jefferies reiterates Dyne Therapeutics stock rating on trial data
Investing.com Analyst Ratings56 · neutralanalyst
Dyne Therapeutics price target lowered to $32 from $50 at H.C. Wainwright
The Fly34 · bearishanalyst
Dyne Therapeutics stock rises on positive DM1 trial results
Investing.com Markets71 · bullishproduct/pr
Dyne Therapeutics, Inc. (DYN) files 8-K
SEC 8-K50 · neutralgeneral
Piper Sandler reiterates Dyne Therapeutics stock rating on drug approval confidence
Investing.com Analyst Ratings63 · neutralanalyst
Piper confident Dyne’s Zeleciment rostudirsen will win January FDA approval
The Fly73 · bullishproduct/pr
Dyne Therapeutics management to meet with Piper Sandler
The Fly55 · neutralgeneral
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes
Stocktwits News38 · neutralgeneral
Dyne extends slide as J.P. Morgan downgrades on Novartis setback
Seeking Alpha34 · bearishanalyst
Dyne Therapeutics stock price target lowered to $30 by RBC Capital
Investing.com Analyst Ratings34 · bearishanalyst
Dyne Therapeutics price target lowered to $36 from $45 at Morgan Stanley
The Fly38 · neutralanalyst
Dyne Therapeutics price target lowered to $30 from $35 at RBC Capital
The Fly34 · bearishanalyst
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class
Seeking Alpha58 · neutralanalyst